Physician profile
Maria E Darland
NPI 1346421351
$6,229.87
in general payments reported to CMS, 2019-2025
30 companies · $906 in 2025
The $906 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $479 · 2021: $495 · 2022: $894 · 2023: $979 · 2024: $1,645 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,402 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,401.92 |
| Education | $127.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,917.09 | 2019-2025 | Tremfya |
| Amgen INC. | $828.01 | 2019-2025 | Tavneos, Evenity, Krystexxa |
| Abbvie INC. | $622.25 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $601.81 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $313.81 | 2019-2025 | |
| Pfizer INC. | $264.96 | 2019-2024 | |
| Glaxosmithkline, LLC. | $228.22 | 2019-2024 | Benlysta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.06 | 2019-2024 | Ofev, Spevigo |
| Lilly USA, LLC | $172.63 | 2019-2024 | Taltz |
| Radius Health, INC. | $160.85 | 2019-2024 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $148.20 | 2019-2023 | |
| Genentech USA, INC. | $96.79 | 2019-2025 | Gazyva, Actemra |
| Horizon Therapeutics Plc | $82.86 | 2022-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $82.23 | 2021-2024 | Acthar |
| Aurinia Pharma U.S., INC. | $78.20 | 2021-2024 | Lupkynis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $51.39 | 2024-2025 | Hyrimoz |
| Astrazeneca Pharmaceuticals LP | $51.35 | 2021-2022 | |
| Boston Scientific Corporation | $50.97 | 2025 | General - Pain Management |
| Regeneron Healthcare Solutions, INC. | $45.72 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $37.27 | 2023-2024 | Idacio |
| Ani Pharmaceuticals, INC. | $30.83 | 2024 | Purified Cortrophin Gel |
| Antares Pharma, INC. | $22.76 | 2020 | |
| Celgene Corporation | $22.74 | 2019 | |
| Mindray Ds USA, INC. | $22.29 | 2023 | Te7 Max, Te X |
| Medtronic, INC. | $22.12 | 2023 | Kyphon Express II Kyphopak Tray |
| Fidia Pharma USA INC. | $21.95 | 2019 | |
| Sobi, INC | $21.45 | 2019 | |
| Pharming Healthcare, INC. | $17.41 | 2024 | Ruconest |
| Merck Sharp & Dohme LLC | $13.68 | 2019 | |
| Genzyme Corporation | $12.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Darland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.